{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T08:51:29Z","timestamp":1768121489693,"version":"3.49.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>Melanoma is characterized by oncogenic mutations in pathways regulating cell growth, proliferation, and metabolism. Greater than 80% of primary melanoma cases harbor aberrant activation of the mitogen-activated protein kinase kinase\/extracellular-signal-regulated kinase (MEK\/ERK) pathway, with oncogenic mutations in BRAF, most notably BRAF V600E, being the most common. Significant progress has been made in BRAF-mutant melanoma using BRAF and MEK inhibitors; however, non-V600 BRAF mutations remain a challenge with limited treatment options. We report the case of an individual diagnosed with stage III BRAF D594G-mutant melanoma who experienced an extraordinary response to the ERK1\/2 inhibitor ulixertinib as fourth-line therapy. Ulixertinib was obtained via an intermediate expanded access protocol with unique flexibility to permit both single-agent and combination treatments, dose adjustments, breaks in treatment to undergo surgery, and long-term preventive treatment following surgical resection offering this patient the potential for curative treatment.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000830","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T14:00:47Z","timestamp":1652364047000},"page":"295-298","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Case report: response to the ERK1\/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma"],"prefix":"10.1097","volume":"32","author":[{"given":"Zachary","family":"Wolfe","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Lehigh Valley Topper Cancer Institute, Allentown, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie C.","family":"Friedland","sequence":"additional","affiliation":[{"name":"xCures, Inc., Oakland, California, Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Ginn","sequence":"additional","affiliation":[{"name":"xCures, Inc., Oakland, California, Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Blackham","sequence":"additional","affiliation":[{"name":"Surgical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Demberger","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Lehigh Valley Topper Cancer Institute, Allentown, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Horton","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Lehigh Valley Topper Cancer Institute, Allentown, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyson","family":"McIntosh","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hina","family":"Sheikh","sequence":"additional","affiliation":[{"name":"Pathology, Lehigh Valley Topper Cancer Institute, Allentown, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Box","sequence":"additional","affiliation":[{"name":"BioMed Valley Discoveries, Kansas City, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Knoerzer","sequence":"additional","affiliation":[{"name":"BioMed Valley Discoveries, Kansas City, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Federowicz","sequence":"additional","affiliation":[{"name":"xCures, Inc., Oakland, California, Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"Stuhlmiller","sequence":"additional","affiliation":[{"name":"xCures, Inc., Oakland, California, Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Shapiro","sequence":"additional","affiliation":[{"name":"xCures, Inc., Oakland, California, Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Lehigh Valley Topper Cancer Institute, Allentown, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"R1-20250528","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.molonc.2011.03.002","article-title":"Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care.","volume":"5","author":"Scolyer","year":"2011","journal-title":"Mol Oncol"},{"key":"R2-20250528","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","article-title":"Current state of melanoma diagnosis and treatment.","volume":"20","author":"Davis","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"R3-20250528","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine.","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod Pathol"},{"key":"R4-20250528","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib.","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"key":"R5-20250528","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"R6-20250528","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2015.09.013","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies.","volume":"53","author":"Ugurel","year":"2016","journal-title":"Eur J Cancer"},{"key":"R7-20250528","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1074\/jbc.RA119.011536","article-title":"Analyses of the oncogenic BRAFD594G variant reveal a kinase-independent function of BRAF in activating MAPK signaling.","volume":"295","author":"Cope","year":"2020","journal-title":"J Biol Chem"},{"key":"R8-20250528","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00195","article-title":"Targeted therapy for colorectal cancers with non-V600 BRAF mutations: perspectives for precision oncology.","volume":"2","author":"Dankner","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"R9-20250528","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/onc.2008.362","article-title":"CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.","volume":"28","author":"Smalley","year":"2009","journal-title":"Oncogene"},{"key":"R10-20250528","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1158\/1078-0432.CCR-19-3443","article-title":"Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: results from NCI-MATCH (EAY131).","volume":"26","author":"Johnson","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R11-20250528","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol"},{"key":"R12-20250528","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00428-015-1784-x","article-title":"Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.","volume":"467","author":"Macerola","year":"2015","journal-title":"Virchows Arch"},{"key":"R13-20250528","doi-asserted-by":"crossref","first-page":"E1130","DOI":"10.1210\/jc.2013-4048","article-title":"TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.","volume":"99","author":"Liu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20250528","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41467-018-03033-1","article-title":"Regulation of mutant TERT by BRAF V600E\/MAP kinase pathway through FOS\/GABP in human cancer.","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"key":"R15-20250528","doi-asserted-by":"crossref","first-page":"15846","DOI":"10.1073\/pnas.2004707117","article-title":"TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles heel.","volume":"117","author":"Tan","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R16-20250528","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.119.227652","article-title":"The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer.","volume":"61","author":"Liu","year":"2020","journal-title":"J Nucl Med"},{"key":"R17-20250528","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/1535-7163.MCT-17-0456","article-title":"Targeting the MAPK signaling pathway in cancer: promising preclinical activity with the novel selective ERK1\/2 inhibitor BVD-523 (Ulixertinib).","volume":"16","author":"Germann","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"R18-20250528","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-Class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study.","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:45:31Z","timestamp":1748468731000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000830","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,12]]}}}